Safe Antibiotics for Hidradenitis Suppurativa Flares in Pregnancy
For pregnant patients with hidradenitis suppurativa flares requiring systemic antibiotics, use oral cephalexin, azithromycin, or clindamycin as first-line options, with rifampin-clindamycin combination reserved for severe disease. 1
First-Line Safe Antibiotic Options
The 2025 North American Clinical Practice Guidelines provide clear guidance on pregnancy-safe antibiotics for HS flares:
Preferred Antibiotics (Moderate Evidence Quality)
- Cephalexin (oral) - Conditional recommendation with moderate-quality evidence supporting safety in pregnancy 1
- Azithromycin (oral) - Conditional recommendation with moderate-quality evidence supporting safety in pregnancy 1
- Clindamycin (oral) - Conditional recommendation with moderate-quality evidence supporting safety in pregnancy 1
These three antibiotics have the strongest safety data from non-HS pregnant populations, showing no significant risks of congenital anomalies or preterm delivery 1.
For Severe Disease Only
Rifampin plus clindamycin combination can be used in select patients with severe HS during pregnancy, though this carries a conditional recommendation with very low evidence quality 1. While rifampin is historically Category C, it is endorsed by the CDC and WHO as first-line treatment for tuberculosis in pregnancy, supporting its safety profile 1. The data on this combination specifically in pregnancy are lacking, so reserve it for severe cases where benefits clearly outweigh theoretical risks.
Important caveat: Clindamycin monotherapy has less robust data supporting its use as monotherapy compared to combination therapy 1.
Antibiotics to Strictly Avoid
The guidelines provide strong recommendations to avoid certain antibiotics due to fetal risks:
Strong Recommendations (Avoid)
- Doxycycline - Risk of congenital anomalies, fetal bone binding, and tooth discoloration 1
- Erythromycin - Risk of elevated liver enzymes and adverse outcomes 1
Conditional Recommendations (Avoid)
- Metronidazole - Increased risk of low birthweight and neuroblastoma 1
- Co-trimoxazole (TMP-SMX) - Increased risk of preterm birth, low birthweight, and kernicterus 1
- Dapsone - Increased risk of preterm birth, low birthweight, and hemolysis 1
Clinical Decision Algorithm
For mild-to-moderate flares:
- Start with cephalexin, azithromycin, or clindamycin monotherapy
- Choose based on patient tolerance and prior response patterns
- These have equivalent safety profiles in pregnancy
For severe flares:
- Consider rifampin-clindamycin combination if disease is severe and unresponsive to monotherapy
- Weigh the theoretical risks of rifampin against the morbidity of uncontrolled severe HS
- Document shared decision-making discussion
For acute, localized flares:
- Intralesional steroids are an option (conditional recommendation, very low evidence) 1
For acute, widespread flares:
- Prednisone may be considered using minimal effective dose and duration (conditional recommendation, low evidence) 1
Common Pitfalls to Avoid
Don't reflexively prescribe doxycycline - Despite being commonly used for HS in non-pregnant patients, it carries strong evidence for fetal harm 1
Don't assume all antibiotics are unsafe - Three antibiotics (cephalexin, azithromycin, clindamycin) have moderate-quality evidence supporting pregnancy safety 1
Don't discontinue effective therapy prematurely - Most women with HS require ongoing management throughout pregnancy, as 72% experience no relief and postpartum flares are common 2
Don't overlook non-antibiotic options - Topical antibiotics, antiseptic washes (chlorhexidine, bleach baths, zinc pyrithione), and zinc supplements are safe adjunctive therapies 1
Additional Safe Treatment Options
Beyond antibiotics, pregnant patients can safely use:
- Topical antibiotics - Similar approach to non-pregnant populations 1
- Antiseptic washes - Chlorhexidine, bleach baths, zinc pyrithione 1
- Zinc supplements - Strong recommendation with moderate evidence 1
- Adalimumab - Strong recommendation with moderate evidence for biologics if already on therapy 1
The evidence strongly supports continuing effective HS management throughout pregnancy rather than accepting disease progression, as uncontrolled HS significantly impacts quality of life and morbidity 1.